BioCentury | Jan 23, 2020
Company News

Thirteen years from founding, Epizyme scores first FDA approval

...go after new classes of epigenetic regulators, when in 2007 it began pursuing inhibitors of histone methyltransferases...
BioCentury | May 30, 2019
Company News

Epizyme looks to sarcoma for first approval

...go after new classes of epigenetic regulators, when in 2007 it began pursuing inhibitors of histone methyltransferases...
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Aug 1, 2018
Distillery Therapeutics

Cancer

INDICATION: Cancer; lymphoma Patient sample, cell culture and mouse studies suggest inhibiting DPY30 could help treat MYC-driven cancers and lymphomas. In tumor samples from B cell lymphoma patients, DPY30 levels were higher in MYC-driven Burkitt...
BioCentury | May 23, 2018
Distillery Therapeutics

Transplant

INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest inhibiting DOT1L or overexpressing DUSP6 could help treat GvHD associated with T cell therapies. In a mouse model of xenogeneic T cell-associated GvHD, adoptive transfer of human CD8...
BioCentury | May 17, 2018
Preclinical News

Targeting DOT1L, DUSP6 to prevent GvHD

In a Nature Communications study , scientists at University Health Network and University of Toronto showed that inhibiting histone methyltransferase DOT1L or promoting dual specificity phosphatase 6 (DUSP6; MKP3) could help prevent graft-versus-host disease induced by...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

...he added. Constellation was founded to move epigenetics beyond HDACs and DNA methyltransferases by targeting histone methyltransferases...
BioCentury | Jun 27, 2017
Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Patient sample and mouse studies suggest inhibiting SIRT1 could help treat osteoarthritis. In cartilage samples from patients, levels of activated DOT1L , a negative regulator of SIRT1, were lower than in samples from non-arthritic...
Items per page:
1 - 10 of 114